Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Fujifilm Expands Cell Culture Capabilities | Contract Pharma

What are you searching for?

Sign in
Breaking News

Fujifilm Expands Cell Culture Capabilities

Launches next gen Apollo X advanced mammalian expression system

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Fujifilm Diosynth Biotechnologies has introduced its next generation Apollo mammalian expression system, Apollo X. The Apollo X advanced mammalian expression system is capable of delivering titres in excess of 10 g/L. 
 
Apollo X is designed to be a ‘manufacturing-ready’ cell line with a robust support package to aid IND filing. 
 
“We have focused on optimizing the cell line development process without compromising quality,” said Andy Topping, chief scientific officer, Fujifilm Diosynth Biotechnologies. “And we have achieved that while reaching titres of 10g/L and higher in fed-batch processes.”
 
Apollo X consists of four key components: (1) a CHO-DG44-derived host cell line selected through a directed evolution approach to control and manage cellular heterogeneity. The selected cell line has been fully sequenced and analyzed; (2) a novel expression vector with a proprietary leader sequence developed for efficient secretion and high productivities without the need for amplification; (3) a proprietary cell culture medium, developed in-house by the Fujifilm group, specifically screened for achieving high titres by monitoring initial cell growth, controlling peak cell density and maintaining high cell viability; (4) streamlined units of operations for efficient process implementation.
 
According to the company, Apollo X cell line development timelines have been reduced by 30%, from gene to clonal cell line compared to the original Apollo expression system.
 
Fujifilm has been aggressively expanding its cell culture capacity at all of its sites since the initial launch of Apollo in 2014.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics